No results found for "".

Commentary & Deal Flow

PX TALK: Biogroup E750m 7NC3 sr sec 3.25-3.50%; E250m 8NC3 sr unsec 5-5.25%

HYC European Market: Deal Flow - General

Biogroup EUR1bn 144A/Reg S 2-part. Via JPM (B&D)/BNP/Natixis joint glocos/Citi/CA/DB/GS/HSBC joint books. List Lux. NY law.

- CAB EUR750m sr sec notes due 2028 (7y). NC3 (50%,25%,par). Equity claw: 3y 40%. B2/B-/B+ (negative/stable/stable). Special call: 10% per year the 1st 3 years at 103. IPT mid to high 3s. Px talk: 3.25%-3.50%.

- Laboratoire Eimer EUR250m sr notes due 2029 (8y). NC3 (50%,25%,par). Equity claw: 3y 40%. Caa1/CCC/CCC+ (negative/stable/stable). IPT mid 5s. Px talk: 5.00%-5.25%.

Did investor call at 10am UKT 01/25. Virtual meetings available 01/25-27. Books close at 10am UKT tomorrow. Pricing tomorrow. UOP: along with a new EUR1.5bn term loan and EUR80m cash on hand, to repay its existing EUR2.015bn term loan, existing EUR305m 2nd lien debt and existing EUR219m PIK notes. Biz: Leading private medical laboratory testing business in France and Belgium.